Toast, Halozyme: Strong Growth, Very Different Risk-Reward

A recent piece grouped Toast, CECO Environmental, and Halozyme Therapeutics together as growth names backed by strong fundamentals. The headline is tidy. The investment reality is not. Two of these three — Toast (NYSE: TOST) and Halozyme (NASDAQ: HALO) — genuinely carry accelerating revenue and rising profits. But one trades at a multiple that demands near-perfect execution for the next two years, while the other just posted the kind of blowout quarter that makes its post-rally price look manageable. Grouping them together obscures that difference.

Toast: Growth Is Real, the Forward Multiple Is Not

Toast reported Q2 2026 revenue of $1.91 billion, up 23.1% year over year, beating consensus by about 1.8%. Annual recurring revenue (ARR) hit $2.4 billion, a 25% increase. Total restaurant locations on the platform reached approximately 180,000, up 22%, with a record 9,500 net new location additions in the quarter. Management raised full-year adjusted EBITDA guidance to $805 million–$825 million and lifted recurring gross profit growth guidance to 23%–25%. The company also repurchased $486 million of shares in the first half of 2026.

This is not a company losing steam. Subscription ARR grew 27%, payments ARR grew 23%, gross payment volume (the total dollar volume of transactions processed through the platform) hit $60.7 billion, and operating income nearly doubled year over year to $152 million.

The problem is the multiple. At a current price of $34.48, Toast trades at 73.3 times forward earnings. For context, the stock's trailing P/E is 41.0x and its enterprise value to trailing EBITDA is 31.5x. That forward multiple implies earnings must grow at a compound rate close to 50% annually just for the multiple to look stable. It also assumes restaurant demand holds, payment processing volumes don't slip, and the company keeps adding roughly 10,000 net locations per quarter through a cyclical industry.

Toast is down 20.2% over the trailing 12 months and sits roughly 24% below its 52-week high of $45.64. The valuation has compressed relative to the high, but 73x forward earnings is still a premium that leaves little margin for error. A deceleration in location adds, a payment processing fee war, or a softer Q3 (the next earnings report arrives August 4, with Q3 guidance already slightly below consensus for EBITDA) would put pressure on the name. The stock is up 17.6% over the past 20 days, which narrows the dip-buying window further.

Toast has real operating momentum. But at 73x forward earnings, that momentum is already reflected in the price. The question isn't whether Toast is a good business. It's whether there's enough upside to justify buying at this multiple.

Rating: Hold.

Halozyme: The Growth Is Faster, the Multiple Is Cheaper

Halozyme reported a record Q2 2026 on August 6, and the market reacted decisively. Revenue reached $481 million, up 48% year over year and well above the $402 million consensus. Non-GAAP EPS came in at $2.28 versus an expected $1.82 — a 25.5% beat. Royalty revenue alone surged 50% to $308 million.

Halozyme's business model is straightforward but powerful. It licenses a protein-based technology (ENHANZE) to pharmaceutical companies, converting slow intravenous infusions into quick subcutaneous injections. Halozyme earns royalties on every sale of the resulting products without manufacturing or selling the drugs itself. Six ENHANZE-enabled products now contribute to royalties, with newer launches — including Opdivo Qvantig, Ocrevus Zunovo, and Rybrevant Faspro — driving approximately 80% of the quarter-over-quarter royalty growth.

The margins reflect the asset-light model. Gross margin sits at 82.8%, operating margin at 33.9%, and free cash flow margin at 44.3%. Free cash flow for the trailing twelve months reached $806 million with 49.1% year-over-year growth.

Management raised full-year 2026 guidance across every metric: total revenue to $1.835 billion–$1.910 billion (31%–37% growth), royalty revenue to $1.220 billion–$1.245 billion (41%–43% growth), adjusted EBITDA to $1.225 billion–$1.280 billion (86%–95% growth), and non-GAAP EPS to $8.65–$9.00 (108%–117% growth). Five new collaboration deals were signed year-to-date, including partnerships with Vertex, GSK, Incyte, and an undisclosed partner in nucleic acid therapeutics — expanding beyond ENHANZE into the Hypercon manufacturing platform and antibody-drug conjugates.

The stock surged 20% in regular trading following the report, closing near $103.12, and is up 53.2% year-to-date. Halozyme trades at just 20.7 times forward earnings. Its trailing P/E is 28.3x, and EV/EBITDA sits at 21.3x.

The Risks That Matter

Halozyme isn't risk-free. ENHANZE patents expire in the early 2030s, which creates a visible gap before the Hypercon platform — management's next-generation manufacturing technology — generates meaningful royalties. Hypercon launches are targeted for 2030–2031, with a goal of $1 billion in annual royalties by the mid-2030s. That timeline is several years away and inherently uncertain.

The balance sheet carries $2.43 billion in total debt against $143.5 million in equity, giving a debt-to-equity ratio of 1,495%. That looks alarming on its own, but interest coverage is strong (the company generates $806 million in free cash flow against roughly $80–100 million in annual interest expense), and the company repurchased $333 million of shares in Q2 alone. The debt is manageable as long as royalty growth holds.

Ongoing intellectual property litigation with Merck and Alteogen adds another layer of uncertainty. Patent challenges could affect ENHANZE's royalty exclusivity.

What the Valuation Gap Says

Put these two side by side and the risk-reward asymmetry is clear:

Metric	Toast (TOST)	Halozyme (HALO)
Revenue growth (YoY)	23%	48%
Gross margin	26.7%	82.8%
FCF margin	8.5%	44.3%
Forward P/E	73.3x	20.7x
EV/EBITDA	31.5x	21.3x

Toast grows faster than most restaurant software companies, but its margins are thin, its forward multiple is stretched, and restaurant cyclicality is a constant overhang. Halozyme grows nearly twice as fast, generates free cash flow on almost half of every dollar of revenue, and trades at a forward multiple less than a third of Toast's — even after a 20% post-earnings rally.

The valuation difference isn't cosmetic. At 73x forward earnings, Toast requires flawless execution through a softening macro environment for restaurants. At 21x forward earnings, Halozyme gives investors room for the patent cliff, litigation risk, and the timeline gap before Hypercon ramps. The royalty engine is diversified across six products and expanding into new modalities, and the guidance raise suggests the pipeline is deeper than the street modeled.

Investor Takeaway

Growth is growth on paper. In practice, growth at 73 times forward earnings and growth at 21 times forward earnings are very different investment propositions.

Halozyme (HALO): Buy. The combination of 48% revenue growth, 83% gross margins, 44% FCF margins, and a forward P/E under 21x is rare in the biotech-adjacent space. The patent cliff and debt load are real risks, but they sit five years out and are partially hedged by the Hypercon pipeline and five new collaboration deals signed in 2026 alone. The post-earnings surge has not stretched the multiple into dangerous territory.

Toast (TOST): Hold. The operating metrics are solid, the location growth is genuine, and management is raising guidance and buying back shares. But the 73x forward P/E means there's little upside left to capture. If the stock pulls back toward the $28–$30 range on a soft restaurant quarter or a macro scare, that would present a more defensible entry. At current levels, the risk-reward doesn't justify buying.

The next catalyst for both names is their Q3 earnings, expected in late October. If Toast can show location adds holding above 8,000 net per quarter and payment volumes tracking in line with guidance, the current multiple becomes tolerable. If Halozyme extends royalty growth into the 40%+ range and signs additional Hypercon deals, the stock has room to move toward the $110 analyst price targets now in play.